Physician

Subhash Proothi, MD

Study Coordinator

Cynthia Evancho
484-658-2534

cynthia.evancho@sluhn.org

Close

Synopsis:  A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma/ Waldenström Macroglobulinemia/ Mantle Cell Lymphoma/ or Marginal Zone Lymphoma Intolerant of Prior Treatment with Ibrutinib

Close

• Is ≥18 years of age, at the time of signing the informed consent
• CLL or SLL, MCL, MZL, or WM with prior documented intolerance (by protocol defined criteria) of ibrutinib or acalabrutinib +/- ibrutinib (at least 4 weeks of prior tx)
• Patients must not have document PD during ibrutinib and/or acalabrutinib treatment- ECOG PS 0-2- No known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation

Close

Physician

Subhash Proothi, MD

Study Coordinator

Cynthia Evancho
484-658-2534
cynthia.evancho@sluhn.org

Close

The purpose of this research is to understand treatment patterns and the effectiveness of drugs used in the treatment of different subtypes of non-Hodgkin lymphoma. The study will include patients starting a second-line treatment for Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL).

Close

• Histologically confirmed DLBCL or folliclar lymphoma
• Previously treated with ≥ 1 prior systemic therapy
• Diagnosis of R/R DLBCL or FL must within 90 days prior to enrollment and patients must intend to initiate 2L systemic treatment
• HSCT following consolidation therapy will be considered as the same line of therapy
• For R/R FL cohort, 2L therapy should not be defined as maintenance therapy

Close